STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.

The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.

Positive
  • None.
Negative
  • None.
0001100682false00011006822025-11-052025-11-05


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


November 5, 2025
Date of Report (Date of earliest event reported)


CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware001-1594306-1397316
(State or Other
Jurisdiction of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)

251 Ballardvale Street
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices) (Zip Code)

781-222-6000
(Registrant’s Telephone Number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueCRLNew York Stock Exchange
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





ITEM 2.02. Results of Operations and Financial Condition
The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On November 5, 2025, Charles River Laboratories International, Inc. issued a press release providing financial results for the third quarter ended September 27, 2025.
The press release, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press release also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission.
ITEM 9.01. Financial Statements and Exhibits
(d) Exhibits.

Exhibit No.Description
99.1
Press release dated November 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
Date:November 5, 2025By:/s/ Matthew L. Daniel
Matthew L. Daniel, Corporate Senior Vice President,
General Counsel, Corporate Secretary & Chief Compliance Officer

3

FAQ

What did CRL disclose in this 8-K?

CRL furnished a press release with financial results for the third quarter ended September 27, 2025, under Item 2.02.

When was the CRL press release issued?

The press release was dated November 5, 2025.

Which exhibit contains the financial results for CRL?

Exhibit 99.1 contains the press release with the third-quarter results.

Are the Item 2.02 disclosures for CRL considered filed?

They are furnished and not deemed filed under the Exchange Act, unless specifically incorporated by reference.

Does the CRL press release include forward-looking statements?

Yes. It includes forward-looking statements with safe harbor language under the Private Securities Litigation Reform Act of 1995.

What period do CRL’s results cover?

The results cover the third quarter ended September 27, 2025.
Charles Riv Labs Intl Inc

NYSE:CRL

CRL Rankings

CRL Latest News

CRL Latest SEC Filings

CRL Stock Data

8.75B
48.60M
1%
105.66%
5.42%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON